🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07124572
Recruiting Observational

Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy

NCT07124572 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Observational
Started
2022-10-01
Last updated
2025-08-15

Condition(s) studied

Thyroid Associated Ophthalmopathy

Investigational drug(s) / intervention(s)

Imaging and ocular examinations

Imaging and ocular examinations: 2D and 3D Facial photography, blinking videos, orbital CT and MRI images, fundus images and images of nine gaze positions are taken. Clinical information is recorded. Quality of life is assessed. Ocular examinations, such as visual acuity, levator function, exophthalmos measurement, strabismus test, visual field examination, axial length measurement, OCT, OCTA are made.

Study summary

This study aims to develop the deep learning-based system that integrates multimodal information to automatically diagnose, stage, and grade thyroid-associated ophthalmopathy (TAO), assist in treatment decision-making, and predict patient prognosis, thereby providing novel tools to support clinical management.

Eligibility

Sex
ALL
Min age
7 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: * normal participants without eyelid disorders (control group) * patients with thyroid-associated ophthalmopathy (TAO group) * cooperative participants Exclusion Criteria: * participants with pupil or cornea disorders * participants with history of eye injury

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Juan Ye Hangzhou Zhejiang Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07124572 on ClinicalTrials.gov ↗ ← All trials in China